Workflow
浙江医药(600216) - 2020 Q1 - 季度财报
600216ZMC(600216)2020-04-23 16:00

Financial Performance - Operating revenue for the first quarter was CNY 1,600,138,984.89, a decrease of 6.89% year-on-year[11]. - Net profit attributable to shareholders was CNY 148,437,811.73, representing an increase of 11.64% compared to the same period last year[11]. - The company reported a net profit excluding non-recurring gains and losses of CNY 100,137,396.63, an increase of 36.07% year-on-year[11]. - The company expects a significant increase in cumulative net profit compared to the same period last year due to substantial price increases for its main products, Vitamin E and Vitamin A, starting from March 2020[27]. - Total operating revenue for Q1 2020 was 1,600,138,984.89,adecreaseof6.91,600,138,984.89, a decrease of 6.9% compared to 1,718,620,418.75 in Q1 2019[45]. - Net profit for Q1 2020 reached 138,459,371.98,anincreaseof12.0138,459,371.98, an increase of 12.0% from 123,589,689.71 in Q1 2019[47]. - The total profit for Q1 2020 was 170,755,643.66,anincreasefrom170,755,643.66, an increase from 144,002,346.92 in Q1 2019[47]. - Q1 2020 net profit reached CNY 198,837,243.75, up 57.5% from CNY 126,032,374.28 in Q1 2019[50]. - Q1 2020 operating profit was CNY 232,594,663.28, an increase of 65.7% compared to CNY 140,331,398.01 in Q1 2019[50]. Cash Flow - Net cash flow from operating activities was CNY 174,563,454.97, a significant increase of 590.00% compared to the previous year[11]. - The cash flow from tax refunds increased by 56.32% to RMB 36,575,884.81, resulting from higher export tax rebates received[22]. - The company recorded a 125.00% increase in cash received from borrowings to RMB 450,000,000.00, reflecting an increase in bank loans[22]. - Q1 2020 cash flow from operating activities was CNY 174,563,454.97, a significant improvement from a negative cash flow of CNY -35,624,950.01 in Q1 2019[55]. - The net cash flow from operating activities for Q1 2020 was ¥275,056,059.85, an increase from ¥155,437,263.45 in Q1 2019, representing a growth of approximately 77%[57]. - The net cash flow from financing activities was ¥292,511,049.22, significantly up from ¥46,392,536.42 in Q1 2019, marking a substantial increase of over 530%[58]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 10,635,984,414.19, an increase of 2.64% compared to the end of the previous year[11]. - The company's cash and cash equivalents increased by 38.14% to RMB 1,765,181,210.52 from RMB 1,277,829,937.33 due to higher net cash flow from operating and financing activities[20]. - Total current assets amounted to RMB 5,304,126,896.41, compared to RMB 5,039,083,988.57 in the previous year[30]. - Total liabilities increased to ¥2,245,182,550.99 from ¥2,110,157,955.49, an increase of about 6.4%[34]. - Current liabilities rose to ¥2,145,773,278.78, compared to ¥2,050,577,560.29, marking an increase of about 4.6%[33]. - Total equity attributable to shareholders rose to ¥8,009,370,573.18 from ¥7,860,815,574.04, reflecting an increase of about 1.9%[34]. Shareholder Information - The total number of shareholders at the end of the reporting period was 45,214[17]. - The largest shareholder, New Changxing Changxin Investment Development Co., Ltd., held 21.57% of the shares[17]. Earnings and Expenses - Basic earnings per share rose to CNY 0.15, up 7.14% from CNY 0.14 in the previous year[11]. - The company reported a financial income of 4,610,136.40inQ12020,comparedto4,610,136.40 in Q1 2020, compared to 1,850,654.73 in Q1 2019[45]. - Research and development expenses for Q1 2020 were 65,922,899.63,slightlyupfrom65,922,899.63, slightly up from 64,247,921.28 in Q1 2019[45]. - The company reported a 58.22% increase in income tax expenses to RMB 32,296,046.59, driven by a rise in the total profit of the parent company[22]. - The company's financial expenses decreased significantly by 131.68% to -RMB 7,121,900.44, mainly due to increased exchange gains[20].